by Steve Bryson, PhD – Multiple Sclerosis Today –
More study needed to support evidence, researchers say.
Mesenchymal stem cell (MSC) therapy is safe and well tolerated, and leads to improvements in disability and a reduction in lesion burden in people with multiple sclerosis (MS), according to a review of published studies.
MSC treatments also reduced levels of biomarkers associated with nerve damage and inflammation, as well as the growth of pro-inflammatory immune cells, while boosting markers of tissue regeneration, neuroprotection, and immune tolerance.
“MSC-based therapies show promising potential as a personalized approach to MS management,” the researchers wrote in the review study, “Immunomodulatory Role of Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review,” which was published in Cureus.
